首页> 外文期刊>Circulation: An Official Journal of the American Heart Association >Influence of diabetes mellitus on inappropriate and appropriate implantable cardioverter-defibrillator therapy and mortality in the multicenter automatic defibrillator implantation trial-reduce inappropriate therapy (MADIT-RIT) trial
【24h】

Influence of diabetes mellitus on inappropriate and appropriate implantable cardioverter-defibrillator therapy and mortality in the multicenter automatic defibrillator implantation trial-reduce inappropriate therapy (MADIT-RIT) trial

机译:在多中心自动除颤器植入试验中,糖尿病对不当和适当的可植入式心脏复律除颤器治疗的影响和死亡率-减少不当治疗(MADIT-RIT)

获取原文
获取原文并翻译 | 示例
           

摘要

Background-The relationship between diabetes mellitus and risk of inappropriate or appropriate therapy in patients receiving an implantable cardioverter-defibrillator (ICD) and resynchronization therapy has not been investigated thoroughly. The effect of innovative ICD programming on therapy delivery in these patients is unknown. Methods and Results-The Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT) randomized patients with a primary prophylactic ICD indication to 3 different types of ICD programming: conventional programming with a ventricular tachycardia zone of 170 to 199 bpm (arm A), high-rate cutoff with a ventricular tachycardia zone =200 bpm (arm B), or 60-second-delayed therapy (arm C). The end points of inappropriate therapy, appropriate therapy, and death were assessed among 485 patients with and 998 without diabetes mellitus. Innovative ICD programming reduced the risk of inappropriate therapy regardless of diabetes mellitus, although a trend toward a more pronounced effect of high-rate cutoff programming was seen in patients without diabetes mellitus (P for interaction=0.06). Diabetes mellitus was associated with a decreased risk of inappropriate therapy (hazard ratio, 0.54; 95% confidence interval, 0.36-0.80; P=0.002) and increased risk of appropriate therapy (hazard ratio,1.58; 95% confidence interval, 1.17-2.14; P=0.003). In diabetic patients, there was significantly increased risk of death in those who had inappropriate therapy (hazard ratio, 4.17; 95% confidence interval, 1.52-11.40; P=0.005) and appropriate therapy (hazard ratio, 2.49; 95% confidence interval, 1.06-5.87; P=0.037) compared with those who did not. Conclusions-Innovative high-rate cutoff or delayed ICD programming was associated with a reduction in inappropriate therapy in patients with and without diabetes mellitus. Diabetes mellitus was associated with lower risk of inappropriate therapy but higher risk of appropriate therapy. Appropriate and inappropriate ICD therapy was associated with increased mortality in diabetic patients. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00947310.
机译:背景-接受植入式心脏复律除颤器(ICD)和同步治疗的患者中,糖尿病与不适当或适当治疗风险之间的关系尚未得到彻底研究。在这些患者中,创新性ICD编程对治疗的影响尚不清楚。方法和结果-多中心自动除颤器植入试验-减少不适当的治疗(MADIT-RIT),将具有主要预防性ICD适应症的患者随机分配到3种不同类型的ICD程序:常规程序,心室心动过速区为170至199 bpm(A组) ),心室心动过速区= 200 bpm的高切除率(B组)或60秒延迟治疗(C组)。在485例糖尿病患者和998例无糖尿病患者中评估了不当治疗,适当治疗和死亡的终点。创新的ICD编程降低了不考虑糖尿病的不适当治疗的风险,尽管在没有糖尿病的患者中观察到了更高的高截止率编程效果的趋势(交互作用P = 0.06)。糖尿病与不适当治疗的风险降低(风险比,0.54; 95%置信区间,0.36-0.80; P = 0.002)和适当治疗的风险增加(风险比,1.58; 95%的置信区间,1.17-2.14 ; P = 0.003)。在糖尿病患者中,如果治疗不当(危险比为4.17; 95%置信区间为1.52-11.40; P = 0.005)和适当的治疗(危险比为2.49; 95%置信区间为: 1.06-5.87; P = 0.037),而没有参加者结论创新的高截止率或延迟的ICD编程可减少和不合并糖尿病患者的不适当治疗。糖尿病与不适当治疗的风险较低,但适当治疗的风险较高。适当和不适当的ICD治疗会增加糖尿病患者的死亡率。临床试验注册网址:http://www.clinicaltrials.gov。唯一标识符:NCT00947310。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号